Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Jazz Pharmaceuticals $500 Million Exchangeable Senior Notes Offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…
Oxford Immunotec Global PLC Offering of Ordinary Shares
Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary…
BeiGene, Ltd. Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public…
Celgene $500 Million Notes Offering
Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million…
Spark Therapeutics Follow-On Offering
Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5…
Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate…
$3.1 Billion Financing for inVentiv’s Merger with INC Research
Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company…
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of…
LabCorp Acquires Chiltern
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2…